33 unknown, 14 not yet recruiting, 11 recruiting, 8 completed. 29 Phase 2, 19 Phase 1, 13 Phase 3, 8 Not applicable, 4 Phase 4.
Follow CSPC Ouyi Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. SYH2066, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 80 | 2026-11-13 | 2026-10-20 |
| A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3) - T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 240 | 2026-11-06 | 2026-09-01 |
| Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. SYH2069 Injection, SYH2069 Injection Placebo - Overweight or Obesity | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 360 | 2026-09-01 | 2026-09-04 |
| A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid Bempedoic Acid Tablet, Placebo - Primary Hyperlipidemia | Phase 3 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 222 | 2026-06-12 | 2026-06-03 |
| A Study of SYH2082 Injection in Healthy Participants SYH2082 Injection, Placebo - Overweight or Obesity | Phase 1 | Active not recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 50 | 2026-04-13 | 2026-07-30 |
| Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. SYH9089 injection, Ropivacaine hydrochloride, 0.9 % sodium chloride - Postoperative Pain | Phase 1 | Recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 60 | 2026-03-30 | 2026-07-15 |
| A Study of SYH2069 Injection in Healthy Participants SYH2069 Injection, Placebo - Overweight or Obesity, Diabetes | Phase 1 | Active not recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 104 | 2026-01-10 | 2026-07-30 |
| Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Mitoxantrone Hydrochloride Liposome & Enlonstobart - Relapsed or Refractory Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-Sen University Cancer Center | 43 | 2025-12-08 | 2025-12-17 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR - Type 2 Diabetes | Phase 3 | Active not recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 815 | 2025-06-20 | 2026-04-06 |
| A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis SYHX1901 - Moderate to Severe Plaque Psoriasis | Phase 3 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 500 | 2025-06-01 | 2025-04-30 |
| Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients SYHX1901, Placebo - Severe Alopecia Areata | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 156 | 2025-05-26 | 2025-06-03 |
| A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Xiaohui He | 33 | 2025-04-16 | 2025-04-10 |
| A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder Dextromethorphan and Bupropion Sustained-Release Tablets, Placebo - Major Depressive Disorder (MDD) | Phase 3 | Recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 388 | 2025-04-11 | 2025-05-06 |
| Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin - Locally Advanced Rectal Cancer | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 68 | 2025-04-01 | 2025-03-25 |
| Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer Liposomal Irinotecan, Oxaliplatin, S-1 - Pancreatic Cancer | Phase 3 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 408 | 2024-09-01 | 2024-08-27 |
| Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma irinotecan hydrochloride liposome injection, Capecitabine, Lenvatinib - Biliary Tract Carcinoma | Not applicable | Not yet recruiting | Yunpeng Liu | 30 | 2024-07-01 | 2024-06-18 |
| Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma irinotecan hydrochloride liposome injection, Capecitabine - Biliary Tract Carcinoma | Phase 2 | Unknown | Ba Yi | 20 | 2024-06-30 | 2024-05-28 |
| Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia Pilocarpine HCl Ophthalmic Solution, Vehicle - Presbyopia | Phase 3 | Unknown | CSPC Ouyi Pharmaceutical Co., Ltd. | 330 | 2024-06-30 | 2024-07-03 |
| A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients SYHX1901, placebo - Non-segmental Vitiligo | Phase 2 | Unknown | CSPC Ouyi Pharmaceutical Co., Ltd. | 144 | 2024-05-27 | 2024-07-22 |
Showing 20 of 72. Sign in to see all of them.
Breast Neoplasms (8) · Lymphoma, T-Cell, Peripheral (4) · Lymphoma, Large B-Cell, Diffuse (3) · Obesity (3) · Overweight (3) · Pancreatic Neoplasms (3) · Stomach Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Biliary Tract Neoplasms (2) · Diabetes Mellitus, Type 2 (2) · Recurrence (2) · Alopecia Areata (1) · Candidiasis, Invasive (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1)
irinotecan sucrosofate (9) · Oxaliplatin (8) · Capecitabine (7) · Carboplatin (7) · 130-nm albumin-bound paclitaxel (6) · Albumin-Bound Paclitaxel (5) · Cyclophosphamide (5) · Fluorouracil (5) · Gemcitabine (5) · Cisplatin (4) · Paclitaxel (4) · S 1 (combination) (4) · liposomal doxorubicin (4) · Docetaxel (3) · Epirubicin (3)
China (59) · United States (1)
Cuizhi Geng, M.D. (2) · Zefei Jiang, M.D. (2) · Baodong Ye (1) · Binghe Xu, PHD (1) · Conghua Xie, Dr (1) · Fang Zhou (1) · Fei Ma, MD (1) · Fenge Yang (1) · Guoping Yang, PhD (1) · Hui Zeng, M.D (1) · Jihui Hao, Ph.D (1) · Jin Zhang, Pro. (1) · Jinhai Ren (1) · Jishi Wang (1)
PMID 32915349, PMID 33435909, PMID 35715774, PMID 35983025, PMID 37201078, PMID 39746964, PMID 40292284, PMID 40819029, PMID 42050512, PMID 42368972